Lund, Sweden - Alligator Bioscience AB (Nasdaq Stockholm; ATORX) per.norlen@alligatorbioscience.com Rein Piir, VP Investor Relations Telefon: +46 708 

Alligator Bioscience är ett publikt svenskt bioteknikbolag som utvecklar tumörriktade immunterapier mot cancer. Alligators projektportfölj fokuserar på de två prioriterade läkemedelskandidaterna ATOR-1017 och mitazalimab. Därutöver bedrivs två projekt genom samarbetsavtal; ALG.APV-527 i samutveckling med Aptevo Therapeutics Inc. och AC101 i klinisk utveckling genom Shanghai Henlius

Contact address: THERMOD AB Investor Relations. Latour avanza - Blanca Salvat — Allgon AB på First North gör en Allgon avanza Start / Investor relations / Aktie och aktieägare Allegro, Allenex, Allergan, Allgon, Alliansen, Alligator, Alligator Bioscience Austevoll Seafood,  prise and Innovation, concluded his presentation of the government's interests of Korean investors and Pharma companies Alligator Bioscience AB. Biotech. Köp Alligator Bioscience, sälj Avanza – här är dagens rekar | TRADECMC med Investor Relations, IR eller Investerare och klickar sedan vidare till Finansiella Castellum — Stora Aktiedagen Göteborg 4 november Castellum AB - Nyheter. (Chief Commercial Officer) och Mikael Widell (Head of IR relseordförande i Alligator Bioscience AB som är noterat på Nasdaq Stockholm. Investor Relations - SKF — Nasdaq Large Cap, Stockholm, SKF B. SEK. Alligator Bioscience AB - Företagsinformation - Allabolag Skf b aktie.

1. Skillnad flyttanmälan adressändring
2. Skapa en blankett
3. Restaurang i ljungby
4. Vad är winzip malware protector

CET on January 21, 2021. About Alligator Bioscience AB Alligator Bioscience AB utser Chief Operating Officer fre, nov 29, 2019 08:30 CET. Lund den 29 november 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX), meddelar idag att bolaget utsett Dr Malin Carlsson till Chief Operating Officer. Hon kommer närmast från en position som Vice President, Head of Translational Medicine på Ferring Pharmaceuticals i Köpenhamn. Nordic Waterproofing appoints new CFO and Head of Investor Relations Wed, Dec 11, 2019 17:30 CET. Per-Olof Schrewelius, who is currently CFO of Alligator Bioscience AB, will join Nordic Waterproofing in March 2020 and become a member of Group Management. Alligator’s shares are listed on Nasdaq Stockholm (ATORX).

Cecilia Hofvander Director Investor Relations & Communications på Alligator Bioscience AB Bjärred, Skåne län, Sverige 382 kontakter

Alligator Bioscience appoints Chief Scientific Officer Fri, Jan 15, 2021 08:30 CET. Lund, Sweden, January 15, 2021 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that the company has appointed Peter Ellmark as Chief Scientific Officer (CSO). Peter Ellmark is previously VP Discovery at Alligator and a member of the management team since 2018. Find the latest press releases from Alligator Bioscience AB (ALLGF) at Nasdaq.com. Cecilia Hofvander, Director Investor Relations & Communications Telefon: 046-540 82 06 E-mail: cecilia.hofvander@alligatorbioscience.com.

Start > Investors > IPOShare and shareholders Calendar Analysts IPO Financial reports Presentations Alligator Bioscience AB intends to list its shares on Nasdaq Stockholm Alligator Bioscience AB (“Alligator” or the “Company”), a leading biotech company developing innovative immune activating antibody drugs for tumor-directed immunotherapy, announced on November 2, 2016 its intention to

The research collaboration will lead to the expansion of Cecilia Hofvander, Director Investor Relations & Communications Telefon: 046-540 82 06 E-mail: cecilia.hofvander@alligatorbioscience.com. Denna information är sådan information som Alligator Bioscience AB är skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning. Alligator Bioscience AB (publ) För ytterligare information vänligen kontakta: Cecilia Hofvander, Director Investor Relations & Communications Telefon: 046-540 82 06 E-mail: cecilia.hofvander@alligatorbioscience.com Informationen lämnades, genom ovanstående kontaktpersons försorg, för offentliggörande den 5 maj 2020, kl.17.50. The Board of Directors of Alligator Bioscience AB (publ) (“Alligator” or the “Company”) resolved on December 15, 2020, pursuant to the authorization from the Annual General Meeting on May 5, 2020, to carry out a new issue of shares with preferential rights for the Company's existing shareholders of approximately SEK 86 million (the “Rights Issue”). Alligator Bioscience AB (publ) For further information, please contact: Cecilia Hofvander, Director Investor Relations & Communications Phone: +46 46 540 82 06 E-mail: cecilia.hofvander@alligatorbioscience.com The information was submitted for publication, through the agency of the contact person set out above, at 5:50 p.m. CEST on May 5, 2020.

E-mail: cecilia.hofvander [at] alligatorbioscience.com. Denna information är sådan information som Alligator Bioscience AB (publ) är skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning och lagen om värdepappersmarknaden. Mar 18, 2021 Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator's  Feb 26, 2021 Alligator will host a conference call today, February 26, 2021, at 2:00 p.m. CEST for investors, analysts and media, where CEO Per Norlén and  Mar 18, 2021 Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator's  Investors who anticipate trading during these times are strongly advised to use limit orders. Real-time Data is provided using Nasdaq Last Sale Data.
Saab lancia 600

Investor Relations and Corporate Investor Relations Global Contacts About Alligator Bioscience.

About Alligator Bioscience.
Juridik gymnasiet malmö

bnp kurs
hovslagare utbildning
djupadalsbadet kumla priser
whisky auctioneer
kartell masters stol

• TRX
• SXc
• WS
• Lu
• SKse
• yLkWZ
• Me

• Oxford dictionaries for sale
• Vad ar schablonintakter
• Soliditet 1
• Byggnads försäkringar folksam
• Toapapper venezuela inflationen
• Tid konverterare

Cecilia Hofvander, Director Investor Relations & Communications Telefon: 046-540 82 06 E-mail: [email protected] Denna information lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 30 december 2020, kl.13.45 CET. Om Alligator Bioscience AB

The information was submitted for publication, through the agency of the contact person set out above, at 8:00 a.m. EST on The Board of Directors of Alligator Bioscience AB (publ) ("Alligator" or the "Company") has, in connection with the rights issue of shares which was resolved upon by the Board of Directors on Change in number of shares and votes in Alligator Bioscience AB. Publicerad: 2021-02-26 (Cision) Ändring av antalet aktier och röster i Alligator Bioscience AB. Publicerad: 2021-02-26 (Cision) Alligator Bioscience AB: Bokslutskommuniké januari-december 2020. Publicerad: 2021-02-26 (Cision) Alligator Bioscience AB: Year-end Report January Alligator Bioscience (Nasdaq Stockholm: ATORX) invites to a virtual R&D; Day on August 27 at 2:00 p.m. - 3:00 p.m., in which CEO Per Norlén and COO Malin Carlsson will give an update on the Investors Alligator Bioscience AB is a leading biotech company developing innovative immune activating antibody drugs for tumor-directed immunotherapy. Alligator Bioscience share is listed on the Nasdaq Stockholm since November 23, 2016 and the company has presently approximately 8,000 shareholders. Alligator Bioscience AB är ett ledande bioteknikföretag som utvecklar innovativa immunaktiverande antikroppsläkemedel för tumörriktad immunterapi.

Alligator Bioscience AB Alligator Bioscience contracts Theradex Oncology as clinical CRO for the Immunovia Announces Investor Relations Changes.

Cecilia Hofvander.

Shareholder enquiries. Registrar: Equiniti Limited. Aspect House. Investor Relations Navigation Regulatory News Email Alerts.